[1]厉 锋,鲍 乐,丁轶人,等.安罗替尼治疗晚期肝癌患者的效果[J].医学信息,2020,33(18):138-140.[doi:10.3969/j.issn.1006-1959.2020.18.045]
　LI Feng,BAO Le,DING Yi-ren,et al.Anlotinib in the Treatment of Patients with Advanced Liver Cancer[J].Medical Information,2020,33(18):138-140.[doi:10.3969/j.issn.1006-1959.2020.18.045]
点击复制

安罗替尼治疗晚期肝癌患者的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年18期
页码:
138-140
栏目:
药物与临床
出版日期:
2020-09-15

文章信息/Info

Title:
Anlotinib in the Treatment of Patients with Advanced Liver Cancer
文章编号:
1006-1959（2020）18-0138-03
作者:
厉 锋; 鲍 乐; 丁轶人; 等
（徐州市肿瘤医院肿瘤内科1，介入科2，外科3，江苏 徐州 221000）
Author(s):
LI Feng; BAO Le; DING Yi-ren; et al
(Department of Oncology1,Department of Intervention2,Department of Surgery3,Xuzhou Cancer Hospital,Xuzhou 221000,Jiangsu,China)
关键词:
安罗替尼; 晚期肝癌; 病情控制率
Keywords:
Anlotinib; Advanced liver cancer; Disease control rate
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2020.18.045
文献标志码:
A
摘要:
目的 观察安罗替尼治疗晚期肝癌患者的临床效果及安全性。方法 回顾性分析2019年2月~2020年3月在我院诊治的50例晚期肝癌患者临床资料，采用随机数字表法将其分为对照组（n=26）和研究组（n=24）。对照组采用索拉非尼治疗，研究组采用安罗替尼治疗，比较两组临床治疗总有效率、病情控制率、肝功能指标[丙氨酸氨基转移酶（ALT）、白蛋白（ALB）、总胆红素（TBIL）]、血清血管内皮生长因子（VEGF）水平、不良反应发生情况以及中位生存时间。结果 研究组病情控制率为29.17%、总有效率为75.00%，与对照组的34.62%、73.08%比较，差异无有统计学意义（P＞0.05）；治疗后，两组ALT、ALB均低于治疗前，差异有统计学意义（P＜0.05），TBIL与治疗前比较，差异无统计学意义（P＞0.05）；研究组ALT、ALB、TBIL与对照组比较，差异无统计学意义（P＞0.05）；研究组手足综合征、蛋白尿、高血压、腹泻、乏力、皮疹、脱发不良反应发生率均低于对照组，差异有统计学意义（P＜0.05）；随访3个月，研究组中位生存时间为（26.11±1.38）个月，长于对照组的（22.40±2.27）个月，差异有统计学意义（P＜0.05）。结论 安罗替尼治疗晚期肝癌效果确切，总有效率和疾病控制率与索拉非尼基本一致，但是安罗替尼不良反应少，可提高患者耐受性，促进治疗顺利进行，进一步延长患者生存时间。
Abstract:
Objective To observe the clinical effect and safety of Anlotinib in the treatment of patients with advanced liver cancer.Methods The clinical data of 50 patients with advanced liver cancer diagnosed and treated in our hospital from February 2019 to March 2020 were retrospectively analyzed, and they were divided into a control group (n=26) and a study group (n=24) using a random number table method.The control group was treated with sorafenib and the study group was treated with anlotinib. The total effective rate, disease control rate, liver function indexes of the two groups were compared between the two groups. [Alanine aminotransferase (ALT), albumin (ALB) , Total bilirubin (TBIL)], serum vascular endothelial growth factor (VEGF) levels, occurrence of adverse reactions, and median survival time.Results The disease control rate of the study group was 29.17% and the total effective rate was 75.00.Compared with 34.62% and 73.08% of the control group, the difference was not statistically significant (P>0.05); after treatment, the ALT and ALB of the two groups were both low before treatment, the difference was statistically significant (P<0.05). There was no statistically significant difference between TBIL and before treatment (P>0.05);There was no significant difference in ALT, ALB, TBIL between the study group and the control group (P>0.05); the incidence of adverse reactions such as hand-foot syndrome, proteinuria, hypertension, diarrhea, fatigue, rash, and alopecia in the study group were lower than those of the control group Group, the difference was statistically significant (P<0.05); follow-up for 3 months, the median survival time of the study group was (26.11±1.38) months, longer than the control group (22.40±2.27) months, the difference was statistically significant (P<0.05).Conclusion Anlotinib had a definite effect in the treatment of advanced liver cancer. The total effective rate and disease control rate were basically the same as those of sorafenib. However, there were few adverse reactions of Anlotinib, which could improve patient tolerance, promote smooth treatment, and further extend the patient survival time.

参考文献/References:

[1]任静.安罗替尼对脂质代谢的调节作用及机制研究[D].天津医科大学,2019．[2]Han BH,Li K,Zhao YZ,et al.Anlotinib as a third-line ther apy in patients with refractory advanced non-small-cell lung cancer：a multicentre，randomised phase Ⅱ trial （AL?TER0302）[J].Br J Cancer,2018,118(5):654-661.[3]中国医师协会肿瘤医师分会,中国临床肿瘤学会血管靶向治疗专家委员会,中国抗癌协会肿瘤靶向治疗专业委员会.盐酸安罗替尼治疗晚期非小细胞肝癌专家共识[J].中华医学杂志,2018,98(44):3561-3567.[4]韩骏,卢实春.晚期肝癌免疫与靶向降期转化治疗的几个要点讨论[J].中华肝胆外科杂志,2020,26(1):67-68. [5]辛涛,金发光,刘伟,等.盐酸安罗替尼胶囊治疗晚期非小细胞肝癌的临床研究[J].中华肺部疾病杂志(电子版),2018,11(5):559-562．[6]Li K,Wang J,Han B,et al.Impact factor analysis for efficacy and prognosis of anlotinib in NSCLC as third-line treatment:data from trial ALTER 0303[J].J Thorac Oncol,2017,12(11):2236.[7]魏照光,陆骊工,邵培坚,等.肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌的临床疗效观察[J].中华放射学杂志,2012,46(3):252-256.[8]王海清,李磊,杨家印.肝癌肝移植术后的复发机制与防治策略[J].中华肝脏病杂志,2018,26(3):93．[9]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肝癌的疗效与安全性[J].中国肿瘤临床,2017,44(3):129-135．[10]李明非,杨远,曾勇,等.TACE 与索拉非尼在晚期肝癌治疗中的疗效比较[J].西部医学,2015,27(9):1299-1302.[11]杨斌,谢辉,王春平,等.安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J].中国医药导刊,2017,19(12):1389－1391．[12]Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.[13]苏雨栋,孟昭婷,徐晓燕,等.安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肝癌杂志,2018,21(5):428-430．[14]Sun Y,Niu W,Du F,et al.Safety，pharmacokinetics，and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors[J].J Hematol Oncol,2016,9(1):105.[15]杨凤伟,张建鑫.安罗替尼治疗晚期肝癌患者的疗效及安全性[J].中国药物经济,2020,15(1):42-45．

相似文献/References:

[1]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(18):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[2]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[3]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
　WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(18):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
[4]阳 芳,黄 斌,覃超群,等.血清KL-6在安罗替尼治疗的非小细胞肺癌中的表达及临床意义[J].医学信息,2023,36(01):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.The Expression and Clinical Significance of Serum KL-6 in Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2023,36(18):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
[5]税 莲,邓海军,刘广国,等.卡培他滨联合安罗替尼三线治疗晚期非小细胞肺癌的安全性和有效性[J].医学信息,2024,37(21):30.[doi:10.3969/j.issn.1006-1959.2024.21.006]
　SHUI Lian,DENG Haijun,LIU Guangguo,et al.Safety and Efficacy of Capecitabine Combined with Anlotinib in the Third-line Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2024,37(18):30.[doi:10.3969/j.issn.1006-1959.2024.21.006]

更新日期/Last Update: 1900-01-01